Issue 32, 2014

Nucleic acid therapeutics: basic concepts and recent developments

Abstract

Nucleic acid based therapeutics have an allure for medicinal chemists due to their potential for specific control of gene expression. Persistent efforts have resulted in the FDA approval of the nucleic acid based drugs Vitravene™, Macugen™ and recently Kynamro™, leading to a sudden leap in the number of active clinical trials involving the nucleic acid moieties. Beginning with antigene and antisense technology, nucleic acid therapeutics have recently gained more potent strategies, e.g. RNA interference, ribozymes, decoy oligonucleotides and aptamers. Nucleic acid based therapeutics which have opened up new frontiers in medicinal chemistry research, along with various chemical modifications undertaken to improve their utility and their mechanism of action, will be discussed in this review article.

Graphical abstract: Nucleic acid therapeutics: basic concepts and recent developments

Article information

Article type
Review Article
Submitted
20 dec 2013
Accepted
13 mar 2014
First published
17 mar 2014

RSC Adv., 2014,4, 16618-16631

Nucleic acid therapeutics: basic concepts and recent developments

V. K. Sharma, P. Rungta and A. K. Prasad, RSC Adv., 2014, 4, 16618 DOI: 10.1039/C3RA47841F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements